Effect of Dapagliflozin on Unconscious functions of the heart in Diabetic Patients.
Phase 3
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2024/04/065339
- Lead Sponsor
- Krishna Keerthi Annepu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Type 2 DM patients
2. Patients who are willing to participate in the study.
Exclusion Criteria
1. Type 1 DM
2. Hypertensives
3. heart failure
4. valvular disease
5. COPD
6. Renal failure
• Patients on drugs like beta-receptor blockers, antihypertensives, sedatives
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The study will evaluate whether taking dapagliflozin will reduce the risk of cardiac autonomic dysfunction compared to a control group among patients with type 2 diabetes mellitus (T2DM).Timepoint: 6 Months
- Secondary Outcome Measures
Name Time Method The study will evaluate the effect of SGLT2 inhibitors on BMI, lipid profile in patients of T2DM.Timepoint: 6 Months